Terbutaline Concentration Research Articles

Adsorption of terbutaline β-agonists from wastewater by mechano-synthesized iron oxide nanoparticles modified copper (II) isonicotinate metal-organic framework

Frequent detection of terbutaline in wastewater highlights its potential risks to human health associated in the environment. Exposure to terbutaline through contaminated water sources or food chain have adverse effects to human health. This work emphasized on the removal of terbutaline from wastewater using adsorption technology. Mechanochemically synthesized [Cu(INA)2] metal-organic frameworks (MOFs) and its magnetic composite ([Cu(INA)2]-MOF@Fe3O4) are designed with higher specific surface areas and tailored features to accommodate the molecular size and structure of terbutaline. Thus, batch experiment has been conducted using the [Cu(INA)2]-MOF and [Cu(INA)2]-MOF@Fe3O4 for the terbutaline adsorption. The adsorption efficiency achieved by the MOFs was 91.8% and 99.3% for the Cu(INA)2]-MOF and [Cu(INA)2]-MOF@Fe3O4 respectively. The optimum for the adsorption study included terbutaline concentration of 40 mg/L, adsorbent dose of 5 mg/L, pH of 11, temperature of 25 °C and equilibrium time of 40 min. The kinetics and isotherms have been described by pseudo-second order and Langmuir models, while the thermodynamics revealed the exothermic and spontaneous nature of the process. The promising performance of the MOFs is manifested on the ease of regeneration and reusability, achieving adsorption efficiency of 85.0% and 94.7% by the Cu(INA)2]-MOF and [Cu(INA)2]-MOF@Fe3O4, respectively at five consecutive cycles. The higher performance of the MOFs demonstrates their excellent potentialities for the terbutaline adsorption from the aqueous solution.

Efficacy of treatment of equine anhidrosis with acupuncture and Chinese herbs is low but higher in treated horses compared with placebo.

To assess the therapeutic efficacy of acupuncture in combination with Chinese herbs for treatment of horses affected with anhidrosis. 44 horses affected with anhidrosis for up to 3 years' duration were enrolled. Inclusion required both compatible clinical signs and results of a quantitative intradermal terbutaline sweat test. Study horses were randomly allocated into 2 groups. Group 1 (n = 19) was treated with daily Chinese herbs and 4 weekly acupuncture sessions. Group 2 (n = 25) was given daily hay powder as a placebo and 4 weekly sham acupuncture sessions. Horses were tested by quantitative intradermal terbutaline sweat test within 2 days after treatment completion and again 4 weeks following treatment. Terbutaline-induced sweat responses (mg) were not different between groups within 2 days and 4 weeks after treatment. Two days after treatment, ratios of sweat responses (compared to baseline) were higher (P < .05) in the treatment group compared to the placebo group at terbutaline concentrations of 1.0, 100, and 1,000 µg/mL. The number of horses responding to treatment was higher in the treatment group (5/19 [26%]), compared to horses in the placebo group (1/25 [4%]) for 1 of 5 terbutaline concentrations 2 days (10 µg/mL) or 4 weeks (0.1 µg/mL) after treatment. Ratios of sweat responses were higher in treatment horses 2 days after treatment, compared to baseline, but not 4 weeks later. The efficacy of a traditional Chinese veterinary medicine protocol for anhidrosis treatment with acupuncture and Chinese herbs was low but higher in treated horses compared with placebo.

Electrospun nanofibers modified with zeolitic imidazolate framework-8 for electrochemiluminescent determination of terbutaline.

For the first time it is demonstratedthat zeolitic imidazolate framework-8 electrospun nanofibers(ZIF-8 NF) could serve as electrochemiluminescence (ECL) accelerator for the facile detection of terbutaline residual. A novel ECL sensor for the determination of terbutaline was fabricated based on ZIF-8 NF. The ZIF-8 NF were successfully prepared according to electrospinning and in-situ growth method. First, chitosan was modified on the surface of the electrode, and then the ZIF-8 NF was modified onto the upper layer of the chitosan. Taking advantages of chitosan and ZIF-8 NF in conductivity and electrocatalysis, the modified electrode presentsobvious ECL phenomenon in 0.2M PBS solution (pH 10.0) containing 0.025M luminol. After the addition of terbutaline, ECL intensity decreased significantly, and the decreasing value showed a linear relationship with the logarithm of terbutaline concentration. The linear range was from 2.0 × 10-10 to 2.0 × 10-5M, and the detection limit was 1.41 × 10-11M (3σ/m). The method had high sensitivity, good stability, and good applicability toactual pork samples.

Assessment of High-Power Electronic Nicotine Delivery System as an Alternative Aerosol Device for Terbutaline Delivery.

The performance of new-generation high-power electronic nicotine delivery system (ENDS) for the administration of inhaled terbutaline was assessed. The formulation of e-liquid was carried out using terbutaline in combination with 1, 3- propanediol. Several terbutaline concentrations (from 0.3125 to 2.500mg / mL) and power levels (from 15 to 35W) were assessed using a box type ENDS. The respirable drug dose was determined using a Glass Twin Impinger and quantified by liquid chromatography coupled with a UV-detector. The Next Generation Impactor and the Dekati Low Pressure Impactor were used to measure the aerosol particle size distribution in drug mass. The results were compared with a jet nebulizer (Cirrus TM 2) similar to the usual clinical conditions (2mL at [terbutaline] of 2.5mg / mL). The optimal conditions to maximize terbutaline delivery using ENDS are a drug concentration at 1mg/mL, and a power level at 30W, to reach a respirable dose of 8.73 ± 0.90µg/puff. By contrast, during a 5min nebulization, the respirable dose of terbutaline was 1040 ± 33µg whatever the cascade impactors and the aerosol devices used. The mass median aerodynamic diameter (MMAD) remains similar for jet nebulizer and ENDS in the 1.74-2.07µm range. Compared to the jet nebulizer, a same respirable dose of terbutaline at the same range of aerosol size distribution was delivered by ENDS if 120 puffs were performed. The ENDS can be considered as an alternative aerosol device for terbutaline delivery.

Chronic treatment with terbutaline increases glucose and oleic acid oxidation and protein synthesis in cultured human myotubes

ObjectiveIn vivo studies have reported several beneficial metabolic effects of β-adrenergic receptor agonist administration in skeletal muscle, including increased glucose uptake, fatty acid metabolism, lipolysis and mitochondrial biogenesis. Although these effects have been widely studied in vivo, the in vitro data are limited to mouse and rat cell lines. Therefore, we sought to discover the effects of the β2-adrenergic receptor agonist terbutaline on metabolism and protein synthesis in human primary skeletal muscle cells. MethodsHuman cultured myotubes were exposed to terbutaline in various concentrations (0.01–30 ​μM) for 4 or 96 ​h. Thereafter uptake of [14C]deoxy-D-glucose, oxydation of [14C]glucose and [14C]oleic acid were measured. Incorporation of [14C]leucine, gene expression by qPCR and proteomics analyses by mass spectrometry by the STAGE-TIP method were performed after 96 ​h exposure to 1 and 10 ​μM of terbutaline. ResultsThe results showed that 4 ​h treatment with terbutaline in concentrations up to 1 ​μM increased glucose uptake in human myotubes, but also decreased both glucose and oleic acid oxidation along with oleic acid uptake in concentrations of 10–30 ​μM. Moreover, administration of terbutaline for 96 ​h increased glucose uptake (in terbutaline concentrations up to 1 ​μM) and oxidation (1 ​μM), as well as oleic acid oxidation (0.1–30 ​μM), leucine incorporation into cellular protein (1–10 ​μM) and upregulated several pathways related to mitochondrial metabolism (1 ​μM). Data are available via ProteomeXchange with identifier PXD024063. ConclusionThese results suggest that β2-adrenergic receptor have direct effects in human skeletal muscle affecting fuel metabolism and net protein synthesis, effects that might be favourable for both type 2 diabetes and muscle wasting disorders.

The Effects of Inhaled Terbutaline on 3-km Running Time-Trial Performance.

Terbutaline is a prohibited drug except for athletes with a therapeutic use exemption certificate; terbutaline's effects on endurance performance are relatively unknown. Purpose: To investigate the effects of 2 therapeutic (2 and 4mg) inhaled doses of terbutaline on 3-km running time-trial performance. Methods: A total of 8 men (age 24.3 [2.4]y; weight 77.6 [8]kg; and height 179.5 [4.3]cm) and 8 women (age 22.4 [3]y; weight 58.6 [6]kg; and height 163 [9.2]cm) free from respiratory disease and illness provided written informed consent. Participants completed 3-km running time trials on a nonmotorized treadmill on 3 separate occasions following placebo and 2- and 4-mg inhaled terbutaline in a single-blind, repeated-measures design. Urine samples (15min postexercise) were analyzed for terbutaline concentration. Data were analyzed using 1-way repeated-measures analysis of variance, and significance was set at P < .05 for all analyses. Results: No differences were observed for completion times (1103 [201]s, 1106 [195]s, 1098 [165]s; P = .913) for the placebo or 2- and 4-mg inhaled trials, respectively. Lactate values were higher (P = .02) after 4mg terbutaline (10.7 [2.3]mmol·L-1) vs placebo (8.9 [1.8]mmol·L-1). Values of forced expiratory volume in the first second of expiration (FEV1) were greater after inhalation of 2mg (5.08 [0.2]; P = .01) and 4mg terbutaline (5.07 [0.2]; P = .02) compared with placebo (4.83 [0.5]L) postinhalation. Urinary terbutaline concentrations were mean 306 (288) ng·mL-1 and 435 (410) ng·mL-1 (P = .2) and peak 956ng·mL-1 and 1244ng·mL-1 after 2 and 4mg inhaled terbutaline, respectively. No differences were observed between the male and female participants. Conclusions: Therapeutic dosing of terbutaline does not lead to an improvement in 3-km running performance despite significantly increased FEV1. The findings suggest that athletes using inhaled terbutaline at high therapeutic doses to treat asthma will not gain an ergogenic advantage during 3-km running performance.

Investigation on a Sensitive Chemiluminescence System Based on Ni(IV) Complex to Determine Two β2-Agonist Drugs in Urine and Swine Feed and Their Mechanism

Veterinary drug residues, particularly traces of β2-agonists, can cause various kinds of harmful impact to the environment and public health. Here, a sensitive chemiluminescence (CL) method incorporated with a flow injection analysis is developed for the determination of two β2-agonists [i.e., salbutamol (SAL) and terbutaline (TEB)]. The system is based on the CL reaction of Ni(IV) complex with luminol in alkaline solutions, whereas SAL and TEB can significantly enhance CL intensities. Under optimum conditions, CL intensities are proportional to the SAL and TEB concentration in the range of 1.0 × 10−9 M to 5.0 × 10−7 M and 1.0 × 10−9 M to 1.0 × 10−7 M, respectively. The limits of detection (3σ) are 1.0 × 10−11 M for TEB, and 1.3 × 10−11 for SAL respectively. Relative standard deviations (n = 11) are less than 2% for 5.0 × 10−8 M SAL and TEB. Possible reaction mechanisms for the CL system are suggested based on the CL system spectra, Ni(IV) complex oxidation characteristics, and electron spin resonance (ESR) techniques. The proposed method has been applied to the analysis of urine and swine feed samples with satisfactory results.

Fabrication of carbon-based nanomaterial composite electrochemical sensor for the monitoring of terbutaline in pharmaceutical formulations

The present investigation is focused on the development of a chemical sensor made by the modification of glassy carbon electrode (GCE) with graphene followed by multi walled carbon nanotubes (MWCNTs) towards the quantitative monitoring of Terbutaline (TB). The developed sensor was characterized with cyclic voltammetry, scanning electron microscopy (SEM) and electrochemical impedance spectroscopy (EIS) studies. The detailed electrochemical redox behavior of TB was examined and possible redox mechanism was proposed. We have studied the effect of pH of phosphate buffer solution (PBS) on the redox behavior of TB and the results suggest that the pH-4.5 was an optimum pH. From the effect of scan rate results, it was concluded that the redox process was controlled by diffusion process and the kinetic parameters were calculated. The effect of concentration of TB was studied and calibration plot was constructed to study the limit of detection and limit of quantification and it was found to be as 6.527×10−7M and 2.175×10−6M respectively. The repeatability, reproducibility and stability of MWCNTs/graphene/GCE, suggest that the developed sensor was superior in condition. The developed sensor was used for the estimation of TB in pharmaceutical formulations and the results were found to be in satisfactory range.

Terbutaline Accumulates in Blood and Urine after Daily Therapeutic Inhalation.

This study investigated pharmacokinetics of terbutaline after single and seven consecutive days of inhalation in exercising trained men. Twelve healthy trained men underwent two pharmacokinetic trials comparing single dose (2 mg) and seven consecutive days (2 mg·d) of inhaled terbutaline. After inhalation of terbutaline at each trial, subjects performed 90 min of bike ergometer exercise at 55%-65% of maximal oxygen consumption after which they stayed inactive. Blood and urine samples were collected before and after inhalation of terbutaline. Samples were analyzed by high-performance liquid chromatography-tandem mass spectrometry. Maximum serum concentration of terbutaline (Cmax) (6.4 ± 1.2 vs 4.9 ± 1.2 ng·mL, P = 0.01) (mean ± 95% confidence interval) and area under serum concentration-time curve from 0 to 4 h after inhalation (AUC0-4) (16 ± 3 vs 13 ± 2 ng·mL·h, P ≤ 0.005) were higher after 7 d of inhalation compared with the first day. Seven days of terbutaline inhalation resulted in accumulation of terbutaline in urine, in which total urine excretion of terbutaline was higher after 7 d of inhalation compared with the first day (274 ± 43 vs 194 ± 33 μg, P ≤ 0.001). These differences were partly attributed to systemic accumulation of terbutaline after consecutive days of inhalation, in that baseline serum and urine samples revealed incomplete elimination of terbutaline. Terbutaline accumulates in serum and urine after consecutive days of inhalation. For doping control purposes, these observations are of relevance if a urine threshold and decision limit is to be introduced for terbutaline on the World Anti-Doping Agency's list of prohibited substances because asthmatic athletes may use their bronchorelievers for consecutive days.

Pharmacokinetics of Oral and Inhaled Terbutaline after Exercise in Trained Men

Aim: The aim of the study was to investigate pharmacokinetics of terbutaline after oral and inhaled administration in healthy trained male subjects in relation to doping control.Methods: Twelve healthy well-trained young men (27 ±2 years; mean ± SE) underwent two pharmacokinetic trials that compared 10 mg oral terbutaline with 4 mg inhaled dry powder terbutaline. During each trial, subjects performed 90 min of bike ergometer exercise at 65% of maximal oxygen consumption. Blood (0–4 h) and urine (0–24 h) samples were collected before and after administration of terbutaline. Samples were analyzed for concentrations of terbutaline by high performance liquid chromatography coupled to tandem mass spectrometry (HPLC-MS/MS).Results: Pharmacokinetics differed between the two routes of administration. Serum Cmax and area under the serum concentration-time curve (AUC) were lower after oral administration compared to inhalation (Cmax: 4.2 ± 0.3 vs. 8.5 ± 0.7 ng/ml, P ≤ 0.001; AUC: 422 ± 22 vs. 1308 ± 119 ng/ml × min). Urine concentrations (sum of the free drug and the glucuronide) were lower after oral administration compared to inhalation 2 h (1100 ± 204 vs. 61 ± 10 ng/ml, P ≤ 0.05) and 4 h (734 ± 110 vs. 340 ± 48 ng/ml, P ≤ 0.001) following administration, whereas concentrations were higher for oral administration than inhalation 12 h following administration (190 ± 41 vs. 399 ± 108 ng/ml, P ≤ 0.05). Urine excretion rate was lower after oral administration than inhalation the first 2 h following administration (P ≤ 0.001). Systemic bioavailability ratio between the two routes of administration was 3.8:1 (inhaled: oral; P ≤ 0.001).Conclusion: Given the higher systemic bioavailability of inhaled terbutaline compared to oral, our results indicate that it is difficult to differentiate allowed inhaled use of terbutaline from prohibited oral ingestion based on urine concentrations in doping control analysis. However given the potential performance enhancing effect of high dose terbutaline, it is essential to establish a limit on the WADA doping list.

Influence of exercise in normal and hot ambient conditions on the pharmacokinetics of inhaled terbutaline in trained men

This study investigated the pharmacokinetics of inhaled terbutaline at rest and after exercise in normal and hot ambient conditions with respect to doping analysis. Thirteen trained young men participated in the study. Urine and blood samples were collected after inhalation of 4mg terbutaline during three trials: exercise in hot ambient conditions (30-35°C) (EXH), exercise in normal ambient conditions (20-25°C) (EX), and rest (20-25°C) (R). Exercise consisted of 130min at various intensities. Adjustment of urine concentrations of terbutaline to a specific gravity (USG) of 1.02g/mL was compared with no adjustment. Area under the serum concentration-time curve within the first 6h was higher for EX (27±3ng/mL/h) (P≤0.01) and EXH (25±4ng/mL/h) (P≤0.05) than for R (20±3ng/mL/h). When unadjusted for USG, urine concentrations of terbutaline after 4h were different in the order EXH>EX>R (P≤0.01). When unadjusted for USG, urine concentrations of terbutaline were 299±151ng/mL higher (P≤0.001) after 4h compared with adjusted concentrations in EXH. Excretion rate of terbutaline was higher (P≤0.001) for EX than for EXH and R within the first 0-1½h. In conclusion, EXHs results in higher urine concentrations of terbutaline. This should be considered when evaluating doping cases of terbutaline.

Macrolide-induced hyperthermia in foals: Role of impaired sweat responses.

The mechanism of hyperthermia, a potentially fatal adverse effect of erythromycin treatment of foals, is unknown. To determine the cause of erythromycin-associated hyperthermia. It was hypothesised that the normal sweat response of foals is impaired by treatment with erythromycin. Blinded, crossover study in 10 healthy pony foals. Foals kept in stalls were given either erythromycin (25mg/kg bwt orally, 3 times daily) or control for 10days then turned out for a further 10days. Quantitative intradermal terbutaline sweat tests were performed on Days 1 (baseline), 3, 10 and 20. The effects on terbutaline-induced sweating of erythromycin, terbutaline concentration and treatment day were analysed by repeated-measures ANOVA with Bonferroni-corrected pairwise post hoc comparisons. Peak temperatures were compared by Wilcoxon's signed rank test and proportions by McNemar's related samples test. Significance was set at P<0.05. There were significant 2-factor interactions for treatment × terbutaline after baseline, treatment × day at every terbutaline concentration, and day × terbutaline for erythromycin (P<0.001) but not control (P=0.9) treatment. Sweating was significantly reduced from baseline in erythromycin-treated foals at all subsequent days. Erythromycin-treated foals produced less sweat at all time-points than did control-treated foals (P<0.05). Peak rectal temperatures of erythromycin-treated foals were significantly higher (P=0.02) than those of controls. During the first 3days outside more erythromycin-treated than control-treated foals required treatment for hyperthermia (6 vs. 0; P=0.03). We believe drug-induced anhidrosis is the likely cause of hyperthermia in some foals treated with erythromycin.

High-dose inhaled terbutaline increases muscle strength and enhances maximal sprint performance in trained men

The purpose of the present study was to investigate the effect of high-dose inhaled terbutaline on muscle strength, maximal sprinting, and time-trial performance in trained men. Nine non-asthmatic males with a VSO₂max of 58.9 ± 3.1 ml min(-1) kg(-1) (mean ± SEM) participated in a double-blinded randomized crossover study. After administration of inhaled terbutaline (30 × 0.5 mg) or placebo, subjects' maximal voluntary isometric contraction (MVC) of m.quadriceps was measured. After MVC, subjects performed a 30-s Wingate test. Sixty minutes following the Wingate test, subjects exercised for 10 min at 80% of VSO₂max and completed a 100-kcal time trial. Aerobic contribution was determined during the Wingate test by indirect calorimetry. Furthermore, plasma terbutaline, lactate, glucose, and K(+) were measured. Inhalation of 15 mg terbutaline resulted in systemic concentrations of terbutaline of 23.6 ± 1.1 ng ml(-1) 30 min after administration, and elevated plasma lactate (P = 0.001) and glucose (P = 0.007). MVC was higher for terbutaline than placebo (738 ± 64 vs. 681 ± 68 N) (P = 0.007). In addition, Wingate peak power and mean power were 2.2 ± 0.8 (P = 0.019) and 3.3 ± 1.0% (P = 0.009) higher for terbutaline than placebo. Net accumulation of plasma lactate was higher (P = 0.003) for terbutaline than placebo during the Wingate test, whereas [Formula: see text] above baseline was unchanged by terbutaline (P = 0.882). Time-trial performance was not different between treatments (P = 0.236). High-dose inhaled terbutaline elicits a systemic response that enhances muscle strength and sprint performance. High-dose terbutaline should therefore continue to be restricted in competitive sport.

Pharmacokinetics of terbutaline in chronic kidney disease

In healthy individuals upwards of 90 % of an injected dose of terbutaline is excreted in the urine. The purpose of this study is to determine the pharmacokinetic properties of terbutaline in patients with severe renal impairment as defined by a glomerular filtration rate (GFR) below 30 mL/min. Ten patients were included in the study. GFR was measured with Cr-EDTA clearance. They were given an intravenous injection of 0.500 mg of terbutaline. Blood samples were collected at intervals for 60 h and urine samples were collected for 96 h. The concentration of terbutaline in the blood and in the urine was used to calculate pharmacokinetic parameters. In patients with normal renal function the total clearance of terbutaline is 2.23-3 mL/min/kg. In our population the total clearance of terbutaline was found to be 1.72 (SD: 0.49) mL/min/kg of which approximately 15 % (0.25 mL/min/kg) was renal clearance. We calculated a distribution volume at steady state of 0.74 (SD: 0.22) L/kg with a terminal half-life of 7.93 (SD: 4.06) hours. The mean residence time (MRT) was 8.35 (SD: 4.93) hours. In healthy individuals the excretion of terbutaline is foremost renal but this study shows that severe renal impairment does not lower the total clearance of terbutaline to a degree that might be expected from the Cr-EDTA clearance. However, more research is needed to determine if dosage adjustment is warranted in patients with CKD.

Modified release terbutaline (SKP1052) for hypoglycaemia prevention: a proof-of-concept study in people with type 1 diabetes mellitus

In this randomized, single blind, cross-over study 2.5 mg and 5 mg of the modified-release terbutaline formulation (SKP-1052) were compared with conventional immediate-release terbutaline (IRT, 5 mg) and placebo on overnight blood glucose (BG) and hypoglycaemia in 30 subjects with type 1 diabetes mellitus. Subjects received subcutaneous injections of insulin glargine (individualized doses) before dinner. SKP-1052, IRT or placebo was administered around 21:00 hours. BG and terbutaline concentrations were monitored overnight for 10 h post-dosing. Endpoints comprised of the nadir BG (BGn 0-10 h, primary endpoint), mean overnight BG (BGmean), morning BG (BGmorning) and hypoglycaemia rates as well as pharmacokinetic (PK) endpoints. SKP-1052 delayed release of terbutaline by 2 h [PK-tmax (mean ± SD) 5.0 ± 2.1 h (2.5 mg) and 4.7 ± 1.7 h (5 mg) vs. 2.6 ± 1.3 h with IRT, p < 0.01, respectively]. Compared with placebo, no significant differences were observed for BGn 0-10 h across treatments, but both 5 mg formulations showed less hypoglycaemic events [10 (IRT), 16 (SKP-1052) vs. 33], higher BGmean (120, 114 and 95 mg/dl) and BGmorning (126, 126 and 101 mg/dl, all comparisons p < 0.05 vs. placebo). Numerically higher BG-levels between 3 and 8 h post-dosing were observed with 2.5 mg SKP-1052 vs. placebo. Compared with IRT SKP-1052 delays release of terbutaline. 2.5 mg SKP-1052 led to numerically higher BG 3 to 8 h post-dose without fasting hyperglycaemia while 5 mg SKP-1052 resulted in fasting hyperglycaemia vs. placebo. Future studies will investigate optimized doses of SKP-1052 for nocturnal hypoglycaemia prevention.

Therapeutic role of terbutaline in a rat whole-lung lavage model

ABSTRACTWhole-lung lavage (WLL) is the preferred therapy for patients with pulmonary alveolar proteinosis (PAP). However, WLL can cause fluid retention, surfactant lost, and hypoxia. Terbutaline has been shown to accelerate the rate of alveolar fluid clearance and augment surfactant secretion. The present study aimed at investigating effects of terbutaline and oxygen ventilation in rats with WLL. Forty rats were randomly divided into control, ventilation, NS (normal saline) + ventilation, LT (terbutaline in low concentration, 10−4 M) + ventilation, and HT (terbutaline in high concentration, 10−3 M) + ventilation groups. The left thoracic cavity was opened and a cannula was inserted into the left bronchus. The left lung was ventilated, while the right lung was lavaged. Arterial blood gas, electrocardiogram, histological changes, and wet/dry ratio of lung tissues were examined. The concentrations of total protein (TP), total phospholipids (TPL), and disaturated phosphatidylcholine (DSPC) in recovery fluid were measured. For the in vitro study, alveolar type II (ATII) cells were isolated from healthy male rats, incubated for 24 hours, and divided into control, LT, and HT groups and exposed to different concentration of terbutaline (10−4 and 10−3 M) for 2 hours, followed by measuring sodium-potassium adenosine triphosphatase (Na+,K+-ATPase) activity. Oxygen ventilation significantly increased Pao2/Fio2 after lavage in the ventilation group, as compared to control group (249.4 ± 7.9 vs 210.6 ± 9.4; P = .001). Compared with NS + venlitation group, a higher concentration of terbutaline decreased the wet/dry ratio of lung tissues (5.0 ± 0.1 vs 5.6 ± 0.1; P = .007), increased the concentrations of TPL (175.9 ± 14.0 vs 162.0 ± 6.8 mg/L; P = .031) and DSPC (93.2 ± 6.9 vs 70.9 ± 6.2 mg/L, P = .0001) in the recovery fluid, and alleviated hypoxia significantly. Terbutaline in both low and high doses increased Na+,K+-ATPase activity in ATII cells (62.5 ± 2.4 and 62.6 ± 2.8 vs 32.2 ± 2.1 mmol/h/mg protein; P < .01). Theses results show that the administration of terbutaline facilitates alveolar fluid absorption and increases surfactant secretion during lung lavage, the former is partly driven by increasing Na+,K+-ATPase activity. The modified lavage method, with the use of terbutaline and oxygen ventilation, is one of potential therapies for patients with PAP.

Quantitative intradermal terbutaline sweat test in horses

The aim of the current study was to quantify sweating responses to intradermal terbutaline in normal horses. Seven Thoroughbred horses were used. Terbutaline (10-fold dilutions from 1000-0.001 mg/l) and a saline control were injected intradermally (0.1 ml/site) and sweat collected for 30 min into absorbent pads taped over each injection site. Tests were performed monthly for 11 successive months and temperature, relative humidity and dewpoint were measured at the time of testing. There was no significant effect (P<or=0.05) of environmental variables or time of year on sweat responses at any dose. There was significant effect (P<0.001) of terbutaline concentration on sweat weight, with significant increases at every concentration from 0.1-1000 mg/l. This quantitative intradermal terbutaline sweat test should be a useful aid to the study of equine sweating and anhidrosis.

Determination of terbutaline with ferrocene-gold colloid-1,4-benzenedimethanethiol layer-by-layer self-assembled gold electrode

Aminylferrocene is successfully immobilized on nanosized gold colloid particles associated with a 1,4-benzenedimethanethiol monolayer on a gold electrode surface and characterized by cyclic voltammograms and electrochemical impedance spectroscopy. In a pH 7.0 phosphate buffer solution, the formal potential (E0’) of Fc is 0.432 V (SCE), and the apparent surface electron-transfer rate constant is 0.89 s−. The immobilized Fc gives an excellent electrocatalytic response to the terbutaline oxidation. The catalytic-current response of differential pulse voltammograms increases linearly with the terbutaline concentration from 1.75 × 10−7 to 5.62 × 10−4 mol/l. The detection limit is 2.30 × 10−8 mol/l. The determination of terbutaline in a tablet dosage is satisfactory. The method is simple, quick, and sensitive.

Micro flow sensor on a chip for the determination of terbutaline in human serum based on chemiluminescence and a molecularly imprinted polymer

Based on a molecularly imprinted polymer (MIP) as the recognition element, a novel chemiluminescence (CL) micro flow sensor on a chip for the determination of terbutaline in human serum is described. The MIP was prepared by using terbutaline as the template, methacrylic acid (MAA) as the functional monomer, ethylene glycol dimethacrylate (EGDMA) as the cross-linking monomer, and acetonitrile as the solvent. The chip was fabricated from two 50 mm × 40 mm × 5 mm transparent poly (methylmethacrylate) (PMMA) slices. The microchannels on the chip etched by CO 2 laser were 200 μm wide and 150 μm deep. The microsensor cell filled with 2 mg MIP for selectively on line adsorbing terbutaline was 10 mm long, 1 mm wide, and 0.5 mm deep. All reagents were controlled by the syringe pump with an accurate timer. The on line adsorbed terbutaline by the MIP can enhance the CL intensity of the reaction of luminol with ferricyanide. The enhanced CL intensity is linear with terbutaline concentration from 8.0 to 100 ng/mL with a detection limit of 4.0 ng/mL (3 σ). The micro flow sensor provides for good reproducibility with the relative standard deviation of 3.6% ( n = 7) for 20 ng/mL terbutaline.

Effect of tocolytics on interleukin-8 production by human amniotic and decidual cells

Preterm labor is associated with the release of various cytokines that play an important role in its pathophysiology. In preterm labor, tocolytics are used to inhibit uterine contractions and prolong gestation. We tested the hypothesis that tocolytics alter endotoxin-induced interleukin (IL-8) production from amniotic and decidual cells in vitro. Amniotic and decidual cells were isolated from patients undergoing elective repeat cesarean section at term. Cells were grown in tissue culture flasks. Cells were subsequently incubated with 100 ng/ml of endotoxin in 24 well plates in the presence of increasing concentrations of magnesium sulfate, nifedipine and terbutaline. After 24 h, IL-8 levels in each well were measured by ELISA. Endotoxin caused a significant elevation in IL-8 production in both amniotic and decidual cells. Magnesium sulfate dose dependently inhibited the endotoxin-stimulated IL-8 production in both decidual and amniotic cells. However, nifedipine and terbutaline did not significantly affect IL-8 production in either cell type. In conclusion, magnesium sulfate differentially suppresses endotoxin-stimulated IL-8 production in amniotic and decidual cells in vitro. The cellular mechanisms of this suppression and its clinical relevance in the setting of preterm labor merit further investigation.